English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background Rapid organism identification (ID) and antimicrobial susceptibility testing (AST) can improve time to adequate therapy (TTAT) and optimal (TTOT). The Accelerate Pheno™ system (ACC) can provide ID and AST results within 7 hours. The objective of this study was to assess the hypothetical impact of ACC on TTAT and TTOT in a hospital with an established antimicrobial stewardship program and rapid genotypic organism and resistance marker ID. Methods Patients with positive blood cultures, at the Detroit Medical Center, from March 29, 2016–June 14, 2016, were retrospectively reviewed. ACC was run on unique blood cultures as part of the laboratory validation of the system. ACC results were not made available to clinicians. These results were utilized to determine the hypothetical impact on TTAT and TTOT that the ACC results would have had in real-time. This assessment was performed based on how clinicians modified antimicrobial therapy with regards to antibiotic choice and timing, once ID or AST were known. The assumption was that the same decisions that were made at the time of traditional AST would have been made when ACC information would have been available. In addition, the impact of ACC on total antimicrobial usage was assessed. Results The analysis included 148 patients. The median actual TTAT was 2.2 hours [interquartile range (IQR) 0.5–12.5 hours]. If ACC results had been available, TTAT could have been improved in 11 patients (7%), with a median potential decrease in the TTAT of 2.3 hours [IQR, 0.8–20.7]. The median actual TTOT was 40.7 hours [IQR, 21.3–74.1]. If ACC results were available, improved TTOT could have been achieved in 59 patients (40%), with a median potential decrease in TTOT of 24.2 hours [IQR 15.3–34.9]. The TTOT would have been achieved by earlier de-escalation in 53/59 (89.8%) patients. ACC implementation could have led to decreases in antibiotic usage for cefepime (17% reduction of actual use), aminoglycosides (23%), piperacillin/tazobactam (8%), and vancomycin (5%). Conclusion Given the aggressive nature of empiric therapy and the availability of other rapid diagnostic tests at our center, ACC would have had a minimal impact TTAT. However, largely due to the ability to more rapidly de-escalate, ACC could have led to a more rapid TTOT in 40% of patients, and significantly reduced the use of broad-spectrum antimicrobials. Disclosures K. Kaye, Zavante Therapeutics, Inc.: Scientific Advisor, Consulting fee.

open forum infectious diseases

2075. The Hypothetical Impact of Accelerate Pheno on Time to Appropriate Therapy (TTAT) and Time to Optimal Therapy (TTOT) in an Institution with an Established Antimicrobial Stewardship Program and Rapid Genotypic Organism/Resistance Marker Identification